

5 April 2024

Osteopore announces 97% take-up for Entitlement Offer

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants is pleased to announce that the Renounceable Pro-Rata Entitlement Offer and Shortfall Offer to raise ~A\$3,000,000 (before costs) (**Entitlement Offer**) closed on 2 April 2024 with strong support from eligible shareholders.

The Entitlement Offer gave eligible shareholders the opportunity to subscribe for ten (10) fully paid ordinary shares (**New Shares**) for every one (1) fully paid ordinary share held (**Shares**) on the Record Date, at an issue price of A\$0.029 per New Share, with 1 free-attaching new option for every 5 New Shares subscribed for (**New Options**) with an accompanying opportunity to subscribe for additional shares under the Shortfall Offer.

The Entitlement Offer was strongly supported by eligible shareholders, who applied for 100,248,212 New Shares, raising approximately \$2,907,000 (before costs) from the Entitlement Offer and Shortfall Offer, which represents an approximate 97% take up rate by eligible shareholders.

The amount raised is subject to change based on the scaling back of funds received, if required, and the withdrawal of applications and refunds of application monies by eligible shareholders up to 6 May 2024.

The announcement of the final results of the Entitlement Offer, with the allocation of shares based on funds raised on the expiration of the withdrawal rights period, is expected to be released to ASX on 7 May 2024.

The issue of New Shares and New Options under the Entitlement Offer is expected to occur on 8 May 2024.

The Company thanks participating shareholders for their ongoing support.



ENDS

This announcement dated 5 April 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim

CEO & CTO

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

E: istewart@canningspurple.com.au

About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

